Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Three new CRISPR-based therapies show promise for treating heart failure through mitochondrial enhancement, cystic fibrosis via lipid nanoparticle gene insertion, and elevated cholesterol with single-dose gene editing targeting ANGPTL3.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07599774 |
Optimal Targeted High-definition Transcranial Direct Current Stimulation for Reducing Post-stroke Upper Limb Motor Impairments |
NOT_YET_RECRUITING | NA |
| NCT07572175 |
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity |
NOT_YET_RECRUITING | PHASE2 |
| NCT07549477 |
A Study of Cardiac Magnetic Resonance Imaging (CMR) for Evaluating Catheter-Associated Right Atrial Clot in People With Cancer |
RECRUITING | NA |
| NCT07541118 |
Evaluating an Implementation Strategy to Improve Physical Activity and Reduce Cardiovascular Risk Factors in Children |
NOT_YET_RECRUITING | NA |
| NCT07518719 |
Feasibility of The Health Integrated Nutrition and Kidney Wellness Program |
NOT_YET_RECRUITING | NA |
| NCT07380243 |
Pathways to Prevention Food-is-Medicine Trial |
RECRUITING | NA |
| NCT07352709 |
Ventilation Performance and Feedback Simulation Trial |
NOT_YET_RECRUITING | NA |
| NCT07290335 |
Optimizing Strategies to Maximize Patient Recruitment Yield |
RECRUITING | NA |
| NCT07251894 |
Pilot Study Exploring the Feasibility, Acceptability, and Impact of Medically Tailored Meals on Post-Discharge Recovery in Patients With Heart Failure |
ENROLLING_BY_INVITATION | NA |
| NCT07212608 |
Personalized Post-Stroke Gait Rehabilitation Interventions |
COMPLETED | NA |
